Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
ZINZINO AB (PUBL): INTERIM REPORT SECOND QUARTER 2023
APRIL-JUNE APRIL-JUNE JANUARY-JUNE Link to the report: https://www.zinzino.com/site/SE/sv-SE/om-oss/investerare/ For more information please contact: Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, email:dag@zinzino.comFredrik Nielsen CFO Zinzino +46 707 900 174, email:fredrik.nielsen@zinzino.com Images for free publication:marketing@zinzino.com Certified Adviser:Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00, email:certifiedadviser@penser...
PR Newswire
31/08/2023
SKF appoints Sophie Arnius as Head of Investor Relations
Aktiebolaget SKF (publ) Aktiebolaget SKF (publ) For further information, please contact:PRESS: Carl Bjernstam, Head of Media Relations tel: 46 31-337 2517; mobile: 46 722-201 893; e-mail:carl.bjernstam@skf.com INVESTOR RELATIONS:Patrik Stenberg, Head of Investor Relations tel: 46 31-337 2104; mobile: 46 705-472 104;patrik.stenberg@skf.com The following files are available for download: View original content:...
PR Newswire
31/08/2023
Change in number of shares and votes in Mendus AB (publ)
As previously announced Mendus AB (publ) (“Mendus”) has carried out a capital raise whereby 472,953,859 new shares were issued in a rights issue and 187,500,000 new shares were issued in a directed issue. As a result thereof, the number of shares and votes in Mendus has changed. The issue of shares has resulted in an increase in the number of shares from 202,694,512 shares to 863,148,371 shares and an increase in the share capital by SEK 33,022,692.95, from SEK 10,134,725.60 to SEK...
Nasdaq GlobeNewswire
31/08/2023
HASEGAWA Corporation Starts Selling New Silk-based Skin-care Products on August…
The concept of LULL is a peaceful, relaxing time brought to users by the feeling of silk on their skin. Silk is suitable for skin-care products because it has an amino acid moisturizing ingredient, similar to the skin. Through silk, LULL delivers to customers an enriched time to cherish themselves. There are five products available now as below. The concept of LULL is a peaceful, relaxing time brought to users by the feeling of silk on their skin. Silk is suitable for skin-care products...
PR Newswire
31/08/2023
GF Extends the Offer Period for the Voluntary Recommended Public Cash Tender…
By August 30, 2023, GF had purchased 6,951,085 Shares in public trading on Nasdaq Helsinki Ltd or otherwise outside the Tender Offer, amounting to 9.5 percent of all issued Shares in Uponor. As of the same date, GF's shareholding plus the irrevocable undertakings in the Tender Offer represented in total 46.4 percent of all issued Shares in Uponor. GF has reserved the right to acquire Shares in Uponor before, during and/or after the offer period in public trading or otherwise. ByAugust 30,...
PR Newswire
31/08/2023
Press Release: Sanofi announces changes to its Executive Committee
Sanofi announces changes toits Executive Committee Paris, August 31 st, 2023. Sanofi announces the following changes to its Executive Committee:HoumanAshrafianis appointed asHead of Research & Development,starting September 11 th, 2023.Madeleine Roachis appointedHead of Business Operations, effective October 1 st, 2023.Emmanuel Frenehardis appointedChief Digital Officer, effective immediately. Bill Sibold ,Head of the Specialty...
Nasdaq GlobeNewswire
31/08/2023
Inventiva announces a financing of approximately €35.7 million from new and…
Daix (France), Long Island City (New York, United States), August 31, 2023– Inventiva (Euronext Paris and Nasdaq: IVA) (the “ Company ”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (“ NASH ”) and other diseases with significant unmet medical needs, today announced an approximately €35.7 million financing.The financing consists of two transactions: (i) a capital...
Nasdaq GlobeNewswire
31/08/2023
INTERIM REPORT FOR Q3 2022/23
In Q3 2022/23, Ambu delivered 8% organic revenue growth and a 7.6% EBIT margin. This was driven by Endoscopy Solutions growing 23%, due to high double-digit growth within urology and ENT, and pulmonology returning to positive growth year-over-year. Today, Ambu narrows its full-year 2022/23 organic revenue growth guidance to 6-8%, previously 5-8%, based on the company's performance in Q3 and the first two months of Q4. On 10 July 2023, Ambu adjusted its financial guidance by upgrading its...
Nasdaq GlobeNewswire
31/08/2023
PCI Biotech first half 2023 interim results
Highlights review fima NAc– bioprocessingThe bioprocessing program for use offima NAc in gene therapy manufacturing has generated new results that add to the initial patent application filed in 2H 2022. Continued focus on generating results that can trigger field testing with potential customers to get feedback and develop a competitive technology. fima NAc– dermatologyFor dermatology the study to demonstrate topicalfima NAc-mediated nucleic...
Nasdaq GlobeNewswire
31/08/2023
IBA Reports Half Year 2023 Results
Read the full half-year 2023 results press release here GROUP NET SALES UP 5.9%BACKLOG CONVERSION TO SIGNIFICANTLY ACCELERATE IN H2CONTINUED INVESTMENT TO PREPARE FOR GROWTH; GUIDANCE REITERATEDLouvain-la-Neuve, Belgium, 31 August 2023- IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its consolidated results for the first half of 2023.(EUR 000)H1 2023H1 2022VarianceVariance %Total Net...
Nasdaq GlobeNewswire
31/08/2023
Vivoryon Therapeutics N.V. to Report Half Year 2023 Financial Results and…
Vivoryon Therapeutics N.V. to Report Half Year 2023Financial ResultsandOperational Progress on September 07 , 2023Halle (Saale) / Munich, Germany , August31 , 2023- Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that it will publish its...
Nasdaq GlobeNewswire
31/08/2023
Junshi Biosciences Announces 2023 Interim Financial Results and Provides…
FINANCIAL HIGHLIGHTSAs of 30 June 2023, the company's total revenue was approximately RMB670 million, representing a decrease of approximately 29% compared to the corresponding period in 2022, which was mainly due to the decrease in income related to out-licensing from overseas. During the Reporting Period, the company's revenue from pharmaceutical products increased significantly. In particular, the sales revenue of TUOYI® (toripalimab) was approximately RMB447 million, representing...
Nasdaq GlobeNewswire
31/08/2023
Anycubic Unveils Game-Changing Wash and Cure Max at Formnext+PM South China 2023
Key Features of the Anycubic Wash and Cure Max: Key Features of the Anycubic Wash and Cure Max: 1. Vast Capacity, Wider Compatibility:The Wash and Cure Max offers an expansive 14.9-liter capacity and a maximum cleaning size of 300x165x300 millimeters, surpassing similar products in the market. It is compatible with consumer-grade light-cured 3D prints up to 13.6 inches and below. 2. Dual-Mode Thorough Cleaning, Reduced Alcohol Usage:Utilizing innovative spray washing and detailed...
PR Newswire
31/08/2023
ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at…
LOTIS-5: Updated safety run-in results from Phase 3 trial demonstrate 80% ORR, 50% CR rate and median DoR of 8 months with no new safety signalsLOTIS-7: Study design of trial evaluating ZYNLONTA ®in patients with r/r non-Hodgkin lymphoma to be highlighted in poster; actively enrolling patients in bispecific combination arms LAUSANNE, Switzerland, Aug.30, 2023(GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that two ZYNLONTA ®(loncastuximab tesirine-lpyl)...
Nasdaq GlobeNewswire
31/08/2023
Natura &Co closes sale of Aesop
The transaction, initially announced on April 3, 2023, will allow Natura &Co to strengthen its balance sheet and focus on its strategic priorities, notably accelerating the integration of the Natura and Avon brands in Latin America, further optimizing Avon International's footprint and continuing to strengthen The Body Shop's business. The transaction, initially announced onApril 3, 2023, will allow Natura &Co to strengthen its balance sheet and focus on its strategic priorities…
PR Newswire
30/08/2023
Essential Thrombocythemia Market to Witness Upsurge in Growth by 2032, Predicts…
Key Takeaways from the Essential Thrombocythemia Market Report Key Takeaways from the Essential Thrombocythemia Market Report Discover which therapies are expected to grab the major essential thrombocythemia market share @Essential Thrombocythemia Market Report Essential Thrombocythemia Overview Essential thrombocythemia is a rare chronic disorder of the bone marrow characterized by an excessive production of platelets, the blood cells responsible for clotting. While the...
PR Newswire
30/08/2023
Information on the Total Number of Voting Rights and Shares
REGULATED INFORMATIONInformation on the Total Number of Voting Rights and SharesMont-Saint-Guibert(Belgium),August 30 , 2023 ,10:30 pmCET / 4:30pm ET–In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 4,925,869.05Total number of securities carrying...
Nasdaq GlobeNewswire
30/08/2023
Alvotech Reports Financial Results for First Six Months of 2023 and Provides…
Product revenue for the first six months of 2023 increased to $22.7 million, compared to $3.9 million for the same period in 2022Investors, including Teva Pharmaceuticals, subscribed to Alvotech's subordinated convertible bonds for an aggregate amount of $140 million in July 2023Expanded its existing commercialization partnerships with Teva Pharmaceuticals for the US and with Advanz Pharma for EuropeSettlement reached with Johnson & Johnson securing a US license entry...
Nasdaq GlobeNewswire
30/08/2023
Philips successfully prices offering of Notes for EUR 500 million to be used for…
Amsterdam, the Netherlands– Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the successful pricing of its issue of EUR 500 million fixed rate notes due 2031 (the “Notes”) under its European Medium Term Note (EMTN) program.The issue of the Notes will have a debt-neutral effect. The net proceeds of the offering will be used for repayment of EUR 500 million utilized and outstanding under the credit facility entered into in Q4 2022 and for...
Nasdaq GlobeNewswire
30/08/2023
The Lab Automation Market is anticipated to grow at a CAGR of around 15% by…
The diverse applications of lab automation systems, including advanced data management, high reproducibility and increased productivity in the biotechnology and pharmaceutical industries, have allowed the researchers to focus on more complex tasks. As a result, several stakeholders have been engaged in the manufacturing of user-friendly, controlled and automated instruments that can be customized as per the needs of the laboratory. The diverse applications of lab automation systems, including...
PR Newswire
30/08/2023
Mallinckrodt Receives Court Approval for "First Day" Motions to Support Ongoing…
As expected, the Court granted Mallinckrodt approval to access $150 million of the $250 million of commitments for new financing it received from certain of its creditors, as well as new borrowing availability from lenders under its asset-based loans. The approvals granted by the Court also enable the Company to continue paying employee wages, salaries and benefits without interruption and to continue paying vendors and suppliers in the ordinary course, including for any pre-petition amounts…
PR Newswire
30/08/2023
The Menarini Group Announces ELZONRIS® (Tagraxofusp) Designated as an Orphan…
Orphan drugs are designated by Japan's MHLW for treatments that are intended for use in fewer than 50,000 patients, where there is also a particularly high medical need. Orphan drug designation can potentially shorten the period required to obtain regulatory approval in Japan by several months, thereby enabling faster patient access. Orphan drugs are designated byJapan'sMHLW for treatments that are intended for use in fewer than 50,000 patients, where there is also a particularly high medical…
PR Newswire
30/08/2023
The Menarini Group Announces ELZONRIS® (Tagraxofusp) Designated as an Orphan…
Orphan drugs are designated by Japan's MHLW for treatments that are intended for use in fewer than 50,000 patients, where there is also a particularly high medical need. Orphan drug designation can potentially shorten the period required to obtain regulatory approval in Japan by several months, thereby enabling faster patient access. Orphan drugs are designated byJapan'sMHLW for treatments that are intended for use in fewer than 50,000 patients, where there is also a particularly high medical…
PR Newswire
30/08/2023
Patient-Derived Xenograft / PDX Model Market worth $687 million |…
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121598251 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121598251 Browse in-depth TOC on "Patient-Derived Xenograft / PDX Model Market"130 - Tables40 - Figures 180 - Pages Patient-Derived Xenograft / PDX Model Market Scope: Mouse model type accounted for the largest share of the patient-derived xenograft/ PDX model market...
PR Newswire
30/08/2023
Altri Comunicati
